Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
Date:5/13/2009

r, for their initiation of a Phase 2 study in Japan. The restructuring initiatives implemented over the last year have resulted in a substantially lower cash burn and we believe that we are sufficiently capitalized to carry out our business plan well into 2010. We are also on track in finding a new chief executive officer who will help us unlock the inherent value of our late-stage clinical pipeline."

On Thursday, May 14, 2009, at 8:30am EDT, the Company will host an investor conference call during which they will provide a brief financial overview of the Company's first quarter financial results and a business outlook for the remainder of 2009.

In order to participate in the conference call, please call 1-877-407-8289 (U.S.), 1-201-689-8341 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM)(ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
3. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
5. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
7. Keryx Biopharmaceuticals Receives Nasdaq Notification
8. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
9. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
10. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
11. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... genetic variant specifically associated with the risk of ... per cent of all breast cancer cases. , ... sub-type, called invasive lobular carcinoma, gives researchers important ... kind of breast cancer, which can be missed ... in the journal PloS Genetics , was ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... as 10 million older Americans suffer from depression, often ... However, new research a project that followed the ... years found that Internet use among the elderly ... 30 percent. , "That,s a very strong effect," said ... information studies and media who led the project. "And ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2
... Strategies for Aging Baby,Boomers, ALEXANDRIA, Va., Jan. 23 ... Florida, the nation,s leading professional,association for assisted living is ... needs of America,s aging population --,especially the "baby-boomers" who ... population in Florida and their families deserve to,know what ...
... five years without anti-rejection drugs , , WEDNESDAY, Jan. ... recipients to stop taking powerful immunosuppressive drugs are starting ... the development of the transplant field is to completely ... lifesaving benefit of the transplant without the costs of ...
... EVANSTON, Ill. --- In early 2007, Northwestern University chemist ... Wright reported in the Journal of Natural Products that ... sponge was extremely effective at inhibiting cancer cell growth. ... and their potential in medicine, Scheidt knew what he ...
... Jan. 23, 2008 -- A review of epidemiological data ... in school may experience a slight but statistically significant ... that could be Alzheimer,s disease. , Scientists at ... School of Medicine in St. Louis reviewed data on ...
... types used frequently in consumer research to the ... of two fundamental needs: they are either promotion-focused, ... and aspirations, or they are prevention-focused, seeking items ... security. According to the research, people are better ...
... Proven Success in School Foodservice to Retail Markets, MUNDELEIN, ... ) announced today the retail launch of its headline-making,salad dressings., ... of Z Trim Ranch, Z,Trim Honey Dijon and Z Trim ... Foods grocery store chain in the Chicago area., "We ...
Cached Medicine News:Health News:Assisted Living Federation Challenges Presidential Candidates 2Health News:New Therapies Could Change Organ Transplants 2Health News:New Therapies Could Change Organ Transplants 3Health News:Synthesis of natural molecule could lead to better anti-cancer drugs 2Health News:Synthesis of natural molecule could lead to better anti-cancer drugs 3Health News:Synthesis of natural molecule could lead to better anti-cancer drugs 4Health News:Less education may lead to delayed awareness of Alzheimer's onset 2Health News:Your personality type influences how much self-control you have 2Health News:Z Trim Holdings, Inc. Launches Innovative Retail Line of Lower Fat Salad Dressings in Upscale Grocery Chain 2Health News:Z Trim Holdings, Inc. Launches Innovative Retail Line of Lower Fat Salad Dressings in Upscale Grocery Chain 3
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
(Date:1/14/2014)... 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio ... acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... of the acquisition were not disclosed. Progressive ... a wide range of sleep, mobility, and respiratory products to ...
(Date:1/14/2014)... Minn. , Jan. 14, 2014   NuAire , a manufacturer ... to agreement with Hitachi Koki of Japan ... in North America . NuAire will utilize its ... and Canada to offer assistance in ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... Mont., Oct. 25 LigoCyte Pharmaceuticals, Inc. ... vaccine products, today announced positive results from a ... particle (VLP) vaccine candidate. Baylor College of Medicine,s ... data from the trial via an oral presentation ...
... Inc. (Nasdaq: ESRX ) announced that it ... 21st Annual Healthcare Conference on Wednesday, November 3, 2010 ... Wednesday, November 10, 2010 at 8:30 a.m. mountain (10:30 ... Tuesday, November 16, 2010 at 9:55 a.m. eastern. These ...
Cached Medicine Technology:Positive Results From LigoCyte's Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting 2Positive Results From LigoCyte's Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting 3Positive Results From LigoCyte's Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting 4Express Scripts to Present at Investor Conferences in November 2
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
... Kit Nebulizer Small Volume Medication Mouthpiece 7FT O ... ,These Sidestream® nebulizers are designed to ... any nebulizer treatment with a fast treatment time. ... 7` (84") tubing and a vent seal adapter ...
Nebulizer Adapter Kit 6"...
... Products, ,Westmed designs, manufacturers and markets ... Respiratory professionals. Our mission is to design ... ability to deliver quality medical care while ... , ,Our web site is designed ...
Medicine Products: